盐酸氮卓斯汀滴眼液治疗儿童变态反应性结膜炎的疗效

观察氮卓斯汀滴眼液治疗儿童变态反应性结膜炎的临床疗效。 方法：变态反应性结膜炎患儿30例随机分为两组：对照组单用玻璃酸钠滴眼液,试验组联合应用玻璃酸钠滴眼液与05g/L盐酸氮卓斯汀滴眼液,治疗前后观察眨眼、眼痒症状、结膜水肿、结膜充血及上、下睑结膜乳头和滤泡、角膜缘腺样增生等体征,评价治疗有效率。 结果：对照组症状、体征评分治疗前后分别为4.60±0.87,472±1.53与2.53±1.45,2.40±1.20;试验组症状、体征评分治疗前后分别为4.72±0.77,5.29±1.46与1.47±1.48,1.59±1.12,两组差异有统计学意义（P<0.05）。对照组与试验组治疗后有效率分别为33%和73%,差异有统计学意义（P<0.05）。 结论：盐酸氮卓斯汀滴眼液是一种有效而安全的治疗儿童变态反应性结膜炎的药物     

富马酸酮替芬滴眼液治疗季节变应性结膜炎眼痒及结膜充血的疗效观察

目的 探讨0.025%富马酸酮替芬滴眼液治疗季节性变应性结膜炎患者眼痒、结膜充血的临床疗效.方法 采用多中心、双盲、随机、平行组别的研究方法,将诊断为季节性变应性结膜炎的229例(229只眼)患者随机分为试验组114例,给予进口0.025%富马酸酮替芬滴眼液,对照组115例,给予0.05%依美斯汀滴眼液,均为2次/d,每次1滴,疗程14d.在用药前和用药后(7±1)d,(14±1)d对两组患者的眼痒和结膜充血进行观察评分.结果 用药后(7±1)d以及(14±1)d,酮替芬组和依美斯汀组眼痒、结膜充血评分均明显下降,与基线期相比差异有统计学意义(P＜0.05);眼痒和结膜充血下降幅度组间(酮替芬一依美斯汀)差异无统计学意义(P＞0.05).结论 进口0.025%富马酸酮替芬滴眼液治疗季节性变应性结膜炎患者的眼痒、结膜充血疗效非劣效于0.05%依美斯汀滴眼液.     

双氯芬酸钠透明质酸钠滴眼液治疗急性变态反应性结膜炎评价

目的 评价0.1%双氯芬酸钠透明质酸钠滴眼液辅助治疗急性变态反应性结膜炎的有效性及安全性的临床评价.方法 对90例(180只眼)急性变态反应性结膜炎患者.包括季节性与常年性变态反应性结膜炎,随机分成三组.A组:对照一组,单用0.05%依美斯汀滴眼液;B组:对照二组,0.05%依美斯汀滴眼液联合0.1%普拉洛芬滴眼液;C组:试验组0.05%依美斯汀滴眼液联合0.1%双氯芬酸钠透明质酸钠滴眼液,三组每种用药均为每日3次.分别于治疗前与治疗后1d、4d、7d、14d随访,评估眼痒、流泪、畏光、异物感等症状与睑结膜乳头和滤泡、分泌物、结膜充血、结膜水肿、角膜缘改变、角膜上皮改变、球周组织水肿等体征,评价有效率及治愈率,并观察用药后眼部不适及副反应.结果 三组患者的一般情况、治疗前症状与体征评分差异均无统计学意义(P＞0.05).A组、B组与C组的治疗有效率在治疗后第1天分别为6.7%、56.7%与60.0%,第4天分别为20.0%、100.0%与96.7%,第7天分别为53.3%、100.0%与100.0%,第14天分别为73.3%、100.0%与100.0%.治疗第14天治愈率分别为10.0%、73.3%与63.3%.两两比较各随访时间点的有效率与治愈率,A组与B组的组间差异均具有统计学意义(P均＝0.000),A组与C组组间的差异均具有统计学意义(P均=0.000),而B组与C组在治疗后各随访时间点的有效率与治愈率相当,差异无统计学意义(P=0.918、0.147、0.058、0.0405＞0.05).各试验组未见用药后的眼部不适及副反应.结论 非甾体类消炎药能快速、有效缓解急性变态反应性结膜炎的症状与体征,其中,0.1%双氯芬酸钠透明质酸钠滴眼液与同类进口滴眼液的疗效相当,是一种有效、安全又经济的变态反应性结膜炎的辅助治疗药物.     

富马酸依美斯汀联合氟米龙滴眼液治疗过敏性结膜炎

目的：评价富马酸依美斯汀滴眼液联合氟米龙滴眼液治疗过敏性结膜炎的疗效。

方法：回顾性研究。选取2020-06/2022-08于我院就诊接受治疗的过敏性结膜炎患者115例230眼,在常规使用富马酸依美斯汀滴眼液治疗的同时根据是否联合使用氟米龙滴眼液分为观察组(56例112眼)和对照组(59例118眼)。分别于治疗前、治疗4 wk后评估两组患者的眼部临床症状和体征评分、泪膜破裂时间(BUT)、角膜荧光素染色评分,并记录治疗期间并发症发生情况。

结果：治疗后两组患者眼部症状和体征评分均降低,且观察组低于对照组(P<0.05); 两组患者BUT均长于治疗前,且观察组长于对照组(P<0.05); 两组患者角膜荧光素染色评分均降低,且观察组低于对照组(P<0.05)。两组患者治疗期间并发症总发生率(3.6% vs 5.1%)无明显差异(P>0.05)。

结论：富马酸依美斯汀滴眼液联合氟米龙滴眼液治疗过敏性结膜炎可明显减轻患者的眼部症状与体征,延长泪膜破裂时间,降低角膜荧光素染色评分,提高疗效,且不增加并发症发生风险,安全性和有效性较高。     

0.1％普拉洛芬滴眼液治疗急性变态反应性结膜炎的疗效

目的评价0．1％普拉洛芬滴眼液治疗急性变态反应性结膜炎的有效性及安全性。方法60例（120眼）急性变态反应性结膜炎患者,包括季节性与常年性变态反应性结膜炎．随机分成两组：对照组单用0．05％富马酸依美斯汀滴眼液．试验组联合应用0．1％普拉洛芬滴眼液与0．05％富马酸依美斯汀滴眼液,两组用药均为每日3次。治疗前与治疗后第1天、第4天、第7天、第14天进行随访,评估眼痒、流泪、畏光、异物感等症状与睑结膜乳头和滤泡、分泌物、结膜充血、结膜水肿、角膜缘改变、角膜上皮改变、球周组织水肿等体征,评价有效率及治愈率,并观察用药后不适感与副作用。结果两组患者的一般情况、治疗前症状与体征评分差异均无统计学意义（P〉0．05）。对照组与试验组的总评分值在治疗后第1天分别为20.30±4．69与12．53±4．12．第4天分别为16．85±3．95与5．93±3．06．第7天分别为12．00±4．26与3．07±3．19,第14天分别为9．45±5．28与1．40±2．46,差异均有统计学意义（P〈0．01）。对照组与试验组在治疗7d后有效率分别为53.3％与100．0％。治愈率分别为6．7％与46．7％;治疗14d后有效率分别为73.3％与100．0％．治愈率分别为10．0％与73．3％．差异均有非常显著的统计学意义（P〈0．01）。试验组未见明显用药后不适感与副作用。结论0．1％普拉洛芬滴眼液能快速、有效地缓解急性变态反应性结膜炎的症状与体征,是一种有效而安全的变态反应性结膜炎的治疗药物。     

过敏性结膜炎的药物治疗

一、控制急性症状的药物(一)眼用抗组胺药常用0．05％依美斯汀(埃美丁)、0．05％氮卓斯汀、0．05％左卡巴斯汀滴眼液等。药理作用:竞争性结合过敏性结膜炎患者睑、球结膜细胞上的组胺受体,阻断组胺导致的扩张血     

盐酸氮卓斯汀联合普拉洛芬治疗儿童变态反应性结膜炎

目的：探讨盐酸氮卓斯汀联合普拉洛芬治疗儿童变态反应性结膜炎的疗效。

方法：选择我院2016-05/2018-06接诊的变态反应性结膜炎患儿80例160眼,根据治疗方法不同分为两组,对照组40例80眼给予普拉洛芬滴眼液治疗,观察组40例80眼在对照组基础上联合盐酸氮卓斯汀滴眼液进行辅助治疗。两组患儿均连续治疗1wk。比较两组患儿临床疗效、临床症状、泪膜稳定性、炎症因子的变化情况及不良反应。

结果：治疗1wk后观察组临床总有效率为95.0%,高于对照组的85.0%(P=0.035)。观察组患儿眼痒、流泪、异物感、畏光的评分均低于对照组\〖(1.13±0.36)vs(2.28±0.41)分,(1.05±0.33)vs(2.14±0.49)分,(1.17±0.46)vs(2.28±0.59)分,(1.29±0.37)vs(1.84±0.55)分\〗(P<0.05); 观察组患儿的泪膜破裂时间(BUT)明显高于对照组,角膜荧光素染色试验(FL)明显低于对照组\〖(11.96±1.14)vs(5.85±0.92)s,(2.85±0.33)vs(6.21±0.68)分\〗(P<0.05); 观察组患儿泪液中组胺(HA)、嗜酸性细胞阳离子蛋白(ECP)和免疫球蛋白E(IgE)水平均低于对照组\〖(31.62±4.51)vs(65.03±6.48)μg/L,(2.20±0.28)vs(7.26±0.72)μg/L,(0.06±0.01)vs(0.18±0.04)mg/L\〗(P<0.05); 两组患儿治疗期间的不良反应总发生率无差异(χ²=1.897,P=0.168)。

结论：盐酸氮卓斯汀联合普拉洛芬治疗儿童变态反应性结膜炎的效果明显,能有效改善炎症因子指标水平,促进泪膜稳定性的恢复,安全性好。     

盐酸左氧氟沙星滴眼液治疗细菌性结膜炎及角膜炎随机双盲对照临床研究

目的　比较北京医工生物技术研究所研制的 15mg/5mL盐酸左氧氟沙星滴眼液和海伦滴眼液治疗细菌性结膜炎、角膜炎的疗效和安全性。方法　用随机、双盲、平行研究。共选择 60例患者分为试验组和对照组各 3 0例。疗程 3～ 14d ,主要疗效参数为治疗第 7、14d的临床疗效。结果　用药 7d细菌性结膜炎和角膜炎试验组总有效率为 72 %( 18/2 5 ) ;对照组总有效率为 84 62 % ( 2 2 /2 6)。用药 14d细菌性结膜炎和角膜炎试验组总有效率为 10 0 % ( 2 5 /2 5 ) ;对照组总有效率为 96 15 % ( 2 5 /2 6) ,两组间细菌性结膜炎和角膜炎总有效率无统计学差异。试验组和对照组对细菌性结膜炎和角膜炎的疗效相当。细菌性结膜炎和角膜炎试验组细菌清除率为 10 0 % ;对照组总清除率 98 0 4% ,两组间清除率比较无显著性差异 (P >0 0 5 )。试验组与对照组均有良好的耐受性 ,无明显不良反应发生。结论　盐酸左氧氟沙星滴眼液治疗细菌性结膜炎和细菌性角膜炎有效且安全。     

新生儿结膜炎诊断及治疗措施探讨

目的:探讨新生儿结膜炎的诊断及治疗措施。方法:将我院2008-01/2010-01收治的新生儿结膜炎患者100例179眼按入院时间顺序随机分为观察组与对照组,每组50例,观察组给予氧氟沙星滴眼液,对照组给予青霉素滴眼液,观察比较两组患儿的疗效、眼分泌物消失时间、结膜充血消失时间、角膜透明时间。结果:治疗后,观察组患儿中有效率为98.0%,显著高于对照组患儿的88.0%(χ2=3.84,P<0.05);观察组患儿的眼分泌物消失时间、结膜充血消失时间、角膜透明时间均明显短于对照组患儿(P<0.01)。结论:氧氟沙星滴眼液治疗新生儿结膜炎疗效极佳,可有效提高治愈率,并缩短患儿的眼分泌物、结膜充血消失时间及角膜透明时间。     

鱼腥草滴眼液治疗流行性角膜结膜炎的临床观察

目的:观察鱼腥草滴眼液治疗流行性角膜结膜炎的临床效果。方法:收集2005-07/2005-09同仁医院门诊急诊就诊的临床确诊为流行性角膜结膜炎的患者40例,随机分为观察组和对照组,分别给予鱼腥草滴眼液和1g/L阿昔洛韦滴眼液点眼,观察6项眼部症状及体征的变化并评分,进行统计学分析。结果:在总的显效率上,两组间差异有统计学意义(P<0.01),观察组优于对照组。用药后第7d,在结膜充血的改善上观察组和对照组间差异有统计学意义(P<0.05);用药后14d,在畏光、异物感、流泪以及结膜充血的改善上两组差异均有统计学意义(P<0.05〉。结论:鱼腥草滴眼液对于治疗流行性角膜结膜炎有明显效果,其疗效优于1g/L阿昔洛韦滴眼液。     

七叶洋地黄双苷滴眼液治疗视屏终端综合征50例

目的:观察七叶洋地黄双苷滴眼液治疗视屏显示终端综合征的临床疗效。方法:对视屏显示终端综合征50例100眼采用七叶洋地黄双苷滴眼液治疗30d,观察治疗前后视觉疲劳9项症状记分。结果:本组50例100眼,治疗前的症状总积分均数为12.64±6.56,治疗后的症状总积分为3.56±4.80分,治疗前后比较,差异有统计学意义(t=8.7409,P<0.01);观察期间,无治疗引起的不良反应。结论:七叶洋地黄双苷滴眼液治疗视屏显示终端综合征近期缓解视觉疲劳症状是安全有效的。     

春季卡他性结膜炎的药物治疗疗效观察

目的临床观察0.1%盐酸奥洛他定滴眼液联合那素达滴眼液治疗春季卡他性结膜炎的疗效。方法对169例患者应用奥洛他定滴眼液滴眼2次/日,共1.5～3个月;那素达滴眼液3次/日点眼,共1个月。于治疗后3、7、14、28 d,2个月、3个月随访观察。结果联合用药后7 d 84.2%的结膜充血消失,14 d时79.7%的眼痒、烧灼感、畏光流泪等症状消失,3个月时治愈率达98.7%。结论奥洛他定联合那素达滴眼液可快速、持久稳定的控制春季卡他性结膜炎的症状及体征。     

Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis

PURPOSE: The efficacy and safety of emedastine 0.05% eye drops (Emadine; Alcon Laboratories, Inc, Fort Worth, Texas), a new H(1) antagonist, were studied in comparison to levocabastine 0.05% eye drops (Livostin; Janssen-Cilag N V, Berchem, Belgium) during a twice-daily treatment schedule for 6 weeks in adult and pediatric patients with seasonal allergic conjunctivitis. METHODS: In a prospective, multicenter, randomized, double-masked, parallel group study, 222 patients with allergic conjunctivitis were randomized (221 received treatment) to either emedastine or levocabastine, instilled twice daily for 6 weeks. Patient diaries were completed four times daily (before the morning and evening instillations, at noon, and in the afternoon), and clinical examinations were conducted at regular intervals. Primary efficacy variables of ocular redness and itching and secondary efficacy variables of chemosis, eyelid swelling, patient diary data, and physician's global assessment were analyzed. RESULTS: Both emedastine and levocabastine produced a statistically significant (P =.0001) reduction in itching and redness within 5 minutes of the first instillation. All signs and symptoms improved progressively over the 6-week treatment period. After 7 days of use, and throughout the remainder of the study, emedastine was statistically superior to levocabastine (P <.006) in preventing and alleviating the signs and symptoms (itching, redness, chemosis, and eyelid swelling) of allergic conjunctivitis. CONCLUSIONS: Emedastine 0.05% eye drops administered twice daily are more efficacious than levocabastine 0.05% eye drops in the prevention and treatment of the signs and symptoms of allergic conjunctivitis in adults and children of 4 years and above. Both emedastine 0.05% eye drops and levocabastine 0.05% eye drops were well tolerated.     

Comparison of emedastine 0.05% or nedocromil sodium 2% eye drops and placebo in controlling local reactions in subjects with allergic conjunctivitis

PURPOSE: To assess the efficacy of nedocromil sodium 2% eye drops and emedastine difumarate 0.05% eye drops in controlling the ocular allergic reaction induced by conjunctival allergen challenge (CAC). METHODS: Thirty subjects with a personal history of allergic conjunctivitis were enrolled (first visit). At the second visit each subject randomly received emedastine 0.05% or nedocromil 2% in one eye and placebo in the other eye. Five minutes after the medication the offending allergen was instilled in both eyes. Ocular redness and itching were evaluated according to a standardized scoring system at 3, 10 and 20-minute intervals after instillation of the allergen. After one week (third visit) the whole procedure was repeated using the placebo in the eye used as control during second visit and one of the trial drug that was not used at second visit in the other eye (either emedastine or nedocromil). RESULTS: Emedastine 0.05% and nedocromil 2% eye drops were more effective than placebo in controlling ocular redness and itching (p<0.01). Emedastine was more effective (p<0.01) than nedocromil in alleviating redness and itching 3 and 10 minutes after application of the allergen. CONCLUSIONS: Emedastine 0.05% appeared superior to nedocromil 2% in producing immediate relief when subjects with allergic conjunctivitis were exposed to the offending allergen.     

加替沙星滴眼液治疗细菌性结膜炎临床分析

目的 探讨加替沙星滴眼液治疗细菌性结膜炎的临床效果.方法 加替沙星组和氧氟沙星组各为120例,合计240例.采用计算机编程随机法,随机双盲对照试验.患者的纳入应能满足所有入选及排除标准,随机分为加替沙星组和氧氟沙星组,分别给予加替沙星滴眼液和相同浓度对照药氧氟沙星滴眼液,疗程7～14天.加替沙星滴眼液组:每日5次,每次1～2滴,滴入结膜囊内,氧氟沙星滴眼液组:每日5次,每次1～2滴,滴入结膜囊内,随诊观察.结果 本研究共分离临床敛病菌67株,其对加替沙星、氧氟沙星、左氧氟沙星和环丙沙星的敏感率分别为98.51%、85.07%、95.52%、78.79%.表明加替沙星的细菌敏感率最高,与氧氟沙星比较,差异有统计学意义.加替沙星滴眼液治疗细菌性结膜炎的疗效不低于氧氟沙星滴眼液.结论 结果表明,加替沙星滴眼液抗菌谱广、抗菌活性强,与氧氟沙星滴眼液疗效相当,安全性好,适于作为细菌性结膜炎的治疗用药.同时对革兰阳性菌和革兰阴性菌感染的眼表疾病,都有一定的治疗效果.

Abstract：

Objective To study the clinical efficacy of gatifloxacin eye drops for bacterial conjunctivitis.Methods A total of 240 cases that diagnosed as bacterial conjunctivitis were randomly divided into test group (gatifloxacin) and control group (floxacin).A random double-blind and paralled study was conducted on 120 cases with gatifloxacin and floxacin eye drops for bacterial conjunctivitis.The drug delivery into conjunctival sac was performed at 7-14 days (one-two drops per time, five times per day).Results Sixty-seven clinical common pathogenic bacteria were separated from the study.The antibacterial activity of gatifloxacin,floxacin, levofloxacin, ciprofloxacin was 98.51%, 85.07%, 95.52%, and 78.79% respectively.The antibacterial activity of gatifloxacin was the highest, and the statistic difference between gatifloxacin and floxacin was found.The effect of gatifloxacin eye drops was not worse than floxacin eye drops.Conclusions The gatifloxacin eye drops has characteristics with broad spectrum, powerfull antibacterial activity.The linical effect of gatifloxacin eye drops is the same with floxacin eye drops.Gatifloxacin eye drops are safe and can be used to treat bacterial conjunctivitis.It has comparatively theropic value of ocular surface disease with Gram-positive bacterial and Gram-negetive bacterial.